Use of lipid-lowering drugs in restricted health access settings: Results from the trends in drug utilization during covıd-19 pandemic in Turkey (PANDUTI-TR) study
| dc.authorid | 0000-0002-8511-6349 | |
| dc.contributor.author | Vızdıklar, Caner | |
| dc.contributor.author | Aydın, Volkan | |
| dc.contributor.author | Tazegül, Gökhan | |
| dc.contributor.author | Kaşkal, Mert | |
| dc.contributor.author | Akıcı, Ahmet | |
| dc.date.accessioned | 2024-06-13T05:22:33Z | |
| dc.date.available | 2024-06-13T05:22:33Z | |
| dc.date.issued | 2024 | |
| dc.department | İstanbul Medipol Üniversitesi, Uluslararası Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Tıbbi Farmakoloji Ana Bilim Dalı | |
| dc.description.abstract | Background: COVID-19 restrictions prompted changes in chronic disease management and lifestyle modifications, potentially altering cardiometabolic indicators and lipid-lowering pharmacotherapy patterns. We aimed to assess lipid-lowering drug (LLD) utilization trends during COVID-19 restrictions. Methods: We obtained nationwide outpatient drug sales and prescribing data for 01.03.2018–31.12.2022 from IQVIA™ Turkey. We evaluated average monthly LLD consumption, their costs, and quarterly prescribing levels in three periods: “before restrictions” (BfR, 01.03.2018–31.03.2020), “during restrictions” (DuR, 01.04.2020–31.03.2022), and “after restrictions” (AfR, 01.04.2022–31.12.2022). Drug utilization was measured via “defined daily dose/1000 inhabitants/day” (DID) metric. Results: LLD utilization increased from 25.4 ± 3.1 DID in BfR to 36.2 ± 6.8 DID in DuR (p < 0.001), and to 42.6 ± 5.3 DID in AfR (p < 0.001 vs. BfR). Statin consumption significantly rose from 22.0 ± 3.0 DID in BfR to 31.6 ± 6.3 DID in DuR (p < 0.001), and further to 37.6 ± 4.7 DID in AfR (p < 0.01 vs. DuR). High-intensity statin consumption elevated by 115.9% in AfR compared to baseline (p < 0.001). Prescribing of LLDs decreased from 12.5 ± 0.6 DID in BfR to 7.2 ± 1.2 DID in DuR (p < 0.001), later reached 13.6 ± 3.8 DID in AfR (p < 0.001 vs. DuR), with prescribing for ongoing users following similar trend. Expenditure on LLDs increased from €8.4 m ± 0.9 m in BfR to €11.4 m ± 2.0 m in DuR (p < 0.001) and to €12.8 m ± 1.9 m in AfR (p < 0.001 vs. BfR). Conclusions: This study revealed a surge in consumption of LLDs in Turkey following the onset of the COVID-19 pandemic. This rise might be related to practices facilitating drug access, in addition to potentially greater adherence, or the necessity for more intense pharmacotherapy due to elevated cardiovascular risk. | |
| dc.description.sponsorship | Health Institutes of Turkiye | en_US |
| dc.identifier.citation | Vızdıklar, C., Aydın, V., Tazegül, G., Kaşkal, M. ve Akıcı, A. (2024). Use of lipid-lowering drugs in restricted health access settings: Results from the trends in drug utilization during covıd-19 pandemic in Turkey (PANDUTI-TR) study. Vascular Pharmacology, 156. http://dx.doi.org/10.1016/j.vph.2024.107382 | |
| dc.identifier.doi | 10.1016/j.vph.2024.107382 | |
| dc.identifier.issn | 1537-1891 | |
| dc.identifier.issn | 1879-3649 | |
| dc.identifier.pmid | 38815702 | |
| dc.identifier.scopus | 2-s2.0-85195070178 | |
| dc.identifier.scopusquality | Q1 | |
| dc.identifier.uri | http://dx.doi.org/10.1016/j.vph.2024.107382 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12511/12636 | |
| dc.identifier.volume | 156 | |
| dc.identifier.wos | 001252586400001 | en_US |
| dc.identifier.wosquality | Q2 | |
| dc.indekslendigikaynak | Web of Science | |
| dc.indekslendigikaynak | Scopus | |
| dc.indekslendigikaynak | PubMed | |
| dc.institutionauthor | Aydın, Volkan | |
| dc.language.iso | en | |
| dc.relation.ispartof | Vascular Pharmacology | en_US |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | COVID-19 Restrictions | |
| dc.subject | Lipid-Lowering Drugs | |
| dc.subject | Medication Use | |
| dc.subject | Statins | |
| dc.title | Use of lipid-lowering drugs in restricted health access settings: Results from the trends in drug utilization during covıd-19 pandemic in Turkey (PANDUTI-TR) study | |
| dc.type | Article |
